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BACKGROUND: To investigate the value of neoadjuvant chemotherapy (NACT), followed by interval debulking surgery (IDS), in
endometrial cancer with transperitoneal spread (stage IV).
METHODS: Patients with endometrial cancer with transperitoneal spread, as determined by laparoscopy (±pleural effusion), were
treated with NACT. Efficacy was determined according to the Response Evaluation Criteria in Solid Tumors, residual tumour at IDS
and histopathological assessment of tumour regression.
RESULTS: A total of 30 patients (median age: 65 years; range:44–81 years) received 3–4 cycles of NACT (83% paclitaxel/carboplatin).
Histopathological subtypes were as follows: serous (90%), clear cell (3%) and endometrioid (6%) carcinoma. Response according to
RECIST was as follows: 2 (7%) complete remission, 20 (67%) partial remission, 6 (20%) stable disease and 2 (7%) progressive disease
(PD). Patients with PD were not operated upon. A total of 24 patients (80%) had optimal cytoreduction (R p1cm), of whom 22
(92%) were without residual tumour. Four patients were considered inoperable and were excluded from further analysis. The median
progression-free survival and overall survival times were 13 and 23 months, respectively.
Histopathological features of chemoresponse in both uterus and omentum were related to a better PFS (P¼0.017, hazard ratio
(HR) ¼0.785) and overall survival (P¼0.014, HR¼0.707). In particular, the absence of tumour infiltration and necrosis were
associated with prognosis.
CONCLUSION: The use of NACT resulted in a high rate (80%) of optimal IDS for the treatment of endometrial cancer with
transperitoneal spread.
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Endometrial cancer is the most frequent malignancy of the female
genital tract in the Western world. The most common subtype is
endometrioid endometrial cancer (EEC) (80%). Uterine papillary
serous carcinoma (UPSC) accounts for 10% and is a highly
aggressive variant that is more likely to spread intraperitoneally,
similar to ovarian cancer (Amant et al, 2005). The incidence of
surgical stage IV disease is B5–10%, with a 5-year overall survival
(OS) ranging from 0–10% (Goff et al, 1994). Despite the poor
outcome, few data exist regarding the optimal management of
patients with stage IV endometrial cancer.
The amount of residual disease after surgery for advanced
endometrial cancer has an impact on median survival and
progression-free interval (PFI) (Goff et al, 1994; Chi et al, 1997;
Bristow et al, 2001; Memarzadeh et al, 2002; Lambrou et al, 2004;
Thomas et al, 2007). These data correspond to findings in ovarian
cancer. Primary debulking is, however, associated with a
considerable rate of postoperative complications: 34–53% in
ovarian cancer (Morice et al, 2003; Hou et al, 2007) and 36–39%
in endometrial cancer (Bristow et al, 2001; Memarzadeh et al,
2002). Moreover, taking into consideration the age and
co-morbidities of endometrial cancer patients, there is a need for
better treatment options.
Neoadjuvant chemotherapy (NACT) has been used in the
treatment of advanced ovarian cancer as an alternative approach
to conventional primary debulking surgery (Chambers et al, 1990;
Vergote et al, 1998; Kayikc¸ioglu et al, 2001; Morice et al, 2003).
A strategy of NACT enables to identify chemo-sensitive disease
that is more likely to benefit from debulking surgery when
compared with chemoresistant disease. Furthermore, resection of a
reduced tumour burden permits less aggressive surgery and can
improve the patients’ quality of life by reduced morbidity and
shorter operations, intensive care unit stays and overall hospitali-
sations. A disadvantage of this neoadjuvant approach was the
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spotential for a worse survival when compared with primary
debulking. In addition, when the neoadjuvant approach was
introduced, some reluctance existed regarding post-chemotherapy
complications at the time of major surgery.
Cytotoxic therapy leads to morphological and histopathological
changes within tumour tissue and in involved stromal tissue.
Successful treatment results in fibrosis and scarring of tumoral
stroma and the surrounding tissue. Histopathological tumour
regression has been established as the gold standard for the
assessment of treatment response in several types of solid tumours
(osteosarcomas, gastric, oesophageal and non-small-cell lung
cancer) (Sassen et al, 2007). A histopathological assessment of
tumour regression in ovarian cancer patients showed a correlation
between the composite pathological tumour response score and
prolonged progression-free survival (Le et al, 2006; Sassen et al,
2007).
In endometrial cancer, the experience of NACT, followed by
interval debulking surgery (IDS), is anecdotal (Resnik and Taxy,
1996; Le et al, 1999; Price et al, 1999; Despierre et al, 2006). Given
the advantages of this strategy, we prospectively investigated the
value of NACT, followed by IDS, for stage IV endometrial cancer,
and tested the hypothesis that the histopathological assessment of
response is predictive for the outcome.
MATERIALS AND METHODS
Between October 1999 and October 2007, patients who were
diagnosed with stage IV endometrial cancer by laparoscopy at the
UZ Gasthuisberg Leuven (Belgium) were enrolled in the study.
Patients with ascites or peritoneal/omental disease diagnosed using
a computed tomography (CT) scan were selected to undergo a
laparoscopy and a curettage. The majority of patients had an
endometrial evaluation showing a primary uterine source. How-
ever, two cases in the beginning of this study were treated as
ovarian cancer, but a final histology at the time of IDS correlated
with endometrial cancer.
The operative notes of the laparoscopy describe the presence of
ascites, the number of metastases and the diameter of the largest
metastases in the following organs: stomach, gallbladder, spleen,
omentum, bladder, colon, rectum, small bowel, uterus, etc. Further,
we describe peritoneal disease at the left and right diaphragm, the
left and right paracolic gutter, pelvis and abdominal wall.
Eligibility criteria were patients with primary and measurable
stage IV endometrial cancer based on transperitoneal spread as
determined by laparoscopy with or without pleural effusion.
Patients who were exposed to ineffective primary surgery resulting
in suboptimal debulking were also included. In our institution,
patients with lung or liver metastases are treated with chemo-
therapy only, unless a complete remission (CR) in these distant
organs is visualised on CT imaging. These patients were excluded
from the study.
All patients received 3–4 cycles of NACT before analysis. In case
of stable disease (SD), partial remission (PR) or CR, IDS was
performed. In case of progressive disease (PD), patients were
excluded from the study. When the patient recovered from surgery,
2–3 additional cycles of chemotherapy were administered.
Efficacy was determined on three levels.
First, response was preoperatively evaluated on imaging studies
using the Response Evaluation Criteria in Solid Tumors (RECIST)
(Therasse et al, 2000). CA-125 levels were available, although the
decision on response was based on RECIST only.
Second, at the time of IDS, response was assessed according to
the macroscopic tumour load at the start and end of surgery. At
the start of IDS, the surgeon made a subjective evaluation of good
or no response to chemotherapy, with good response indicating
that the tumour was replaced by an avascular and fibrotic lesion.
Residual tumour was assessed at the end of surgery according to
the following definitions: complete cytoreduction (no residual
tumour), optimal cytoreduction (residual tumour o1cm) and
suboptimal cytoreduction (residual tumour of 41cm).
Third, a histopathological analysis was carried out on tumour
specimens that were obtained during IDS on the basis of the
methodology described by Sassen et al (2007). Eight histopatho-
logical features of tumour regression were assessed in the uterus
and omentum, namely, the presence of fibrosis, necrosis,
inflammatory cell infiltrates, foamy macrophages, isolated psam-
moma bodies, giant cells of foreign-body type, giant tumour cells
and pattern of tumour infiltration. For each feature, three grades
were defined as follows: not or minimally present (0/1þ), focal
occurrence (2þ) and widespread occurrence within the surgical
specimen (3þ). Fibrosis was classified as a regressive change only
when extensive fibrosis was associated with little or no residual
tumour.
The pattern and extent of tumour infiltration were classified as
follows: macroscopic large confluent tumour mass (1þ), multiple
small tumour foci (2þ) and scattered solitary tumour cells or a
complete absence of residual tumour (3þ).
An ‘overall tumour regression score’ was derived by adding the
extent of regressive changes (0/1þ¼1; 2þ¼2; 3þ¼3) for all
eight histopathological features in both organs. This overall
tumour regression score can vary between 16 and 48, and was
linked to progression-free survival (PFS) and OS using the Cox
proportional hazards regression model. This allowed us to assess
whether these regressive changes were an indicator of treatment
response.
We controlled for the CA-125 level and response on CT by
adding these as covariates. The limited sample size and number of
events prohibited the investigation of more covariates (Vittinghoff
and McCulloch, 2007).
Results were summarised by hazard ratio (HR), together with
95% profile likelihood confidence intervals (CIs). HR estimates
the change in hazard of recurrence or death for a unit increase in
the overall tumour regression score. The proportional hazards
assumption was checked.
RESULTS
A total of 30 patients were enrolled in the study and their
characteristics are shown in Table 1. The number of treatment
adjustments due to grade 3–4 bone marrow toxicity is summarised
in Table 2.
Preoperative response after NACT
Response evaluation according to the RECIST criteria was as
follows: CR in 2 (7%) patients, PR in 20 (67%) patients and SD in 6
(20%) patients. The response rate was 74%. A total of 2 patients
(7%) showed progression.
Response at IDS
During surgery, 4 (13%) patients were considered inoperable for
the following reasons: invasion in bladder and rectum (n¼1),
involvement of superior mesenteric artery/porta hepatis (n¼2)
and extensive retroperitoneal disease (n¼1). A total of 24 patients
underwent IDS. According to the macroscopic tumour load, 20
patients (83%) showed clear signs of chemosensitivity, 2 (8%) had
no obvious signs and data were not available for 2 (8%) patients.
Surgical procedures were as follows: total abdominal hysterectomy
with bilateral salpingo-o ¨phorectomy and omentectomy (n¼24),
pelvicþparaaortic lymphadenectomy (n¼12), douglasectomy
(n¼9), stripping of the diaphragm (n¼2) and coagulation of
the diaphragm (n¼7). No splenectomy or bowel resections were
performed.
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reduction (no residual tumour) and 2 (8%) had optimal cyto-
reduction (multiple lesions of o1 and 0.5cm in each patient).
The pathology report of uterine specimens showed mainly a
poorly differentiated serous papillary carcinoma (n¼18), a well-
differentiated endometrioid carcinoma (n¼1) and only endo-
metrial intraepithelial carcinoma (EIC) (n¼3). In two cases, no
residual tumour was found in the endometrium/myometrium.
Myometrial invasion to the outer half was reported in 10 cases,
cervical stromal invasion in 4 cases and lymph vessel space
involvement in 8 cases. Of the 12 patients who underwent a
lymphadenectomy, 6 (50%) showed node involvement.
The median PFS time was 13 months, indicating that 50% of
patients experienced disease progression within 13 months (Figure 1).
The median OS time was 23 months (Figure 1). All patients of the
group who were progressive or inoperable (n¼6) died of disease.
M e d i a nO Sw a s1 2m o n t h s( r a n g e :5 – 2 4 )f o rt h i sg r o u p .
A total of 3 (13%) patients showed minor postoperative
complications (urinary tract infection and prolonged time to
bowel movement) and 1 (4%) patient needed a re-laparotomy
because of internal bleeding.
Histopathological response
A total of six patients were excluded because of PD or
inoperability. A total of 24 patients received 2–5 cycles of
postoperative chemotherapy, shown in Table 2.
The results for the eight assessed features of histopathological
tumour regression in the uterus and omentum are shown in
Table 3 and illustrated in Figure 2.
Using Cox regression, we observed that the overall extent of
tumour regression was related to a better PFS (HR¼0.785, 95% CI
0.599–0.964) and a better OS (HR¼0.707, 95% CI 0.482–0.943).
These effects are visualised by Kaplan–Meier curves for the best
and worst scoring patients on the basis of a median split (Figure 3).
Statistically controlling for CA-125 and response on CT did not
change the results for PFS (HR¼0.733, 95% CI 0.539–0.934) or OS
(HR¼0.692, 95% CI 0.479–0.923).
The features ‘fibrosis’, ‘necrosis’ and grade of ‘tumour infiltra-
tion’ were more often present than were other regressive changes
(Table 3), and were separately analysed to tentatively investigate
which features contributed most to the effect of the overall tumour
regression score. It was suggested that less tumour infiltration and
more necrosis were related to better PFS (infiltration: HR¼0.721,
95% CI 0.475–1.081; necrosis: HR¼0.341, 95% CI 0.087–0.878)
and better OS (infiltration: HR¼0.717, 95% CI 0.445–1.140;
necrosis: HR¼0.215, 95% CI 0.036–0.682), in contrast to fibrosis.
DISCUSSION
The clinical decision making for advanced stage endometrial cancer
should preferably take morbidity attributed to primary debulking
surgery into consideration. Endometrial cancer also frequently affects
old and fragile women. Balancing between chemotherapy (without
surgery) and aggressive cytoreductive surgery, when sensitivity to
chemotherapy is not known, the use of NACT followed by IDS might
be a valuable option. This study showed that this strategy is a valuable
a l t e r n a t i v ea sw ew e r ea b l et oi d e n t i f yc h e m o r e s i s t a n td i s e a s e( a n d
hence poor candidates for any surgery) and, given the high rate of
complete cytoreduction, a low complication rate. These results
confirm earlier case reports on this subject (Resnik and Taxy, 1996;
Le et al, 1999; Price et al, 1999). It appears from Table 3 that all five
previously published cases had CR or PR based on imaging studies
and all had no residual disease after IDS.
Table 2 Overview of treatment adjustment because of haematological
toxicity in neo-adjuvant period and postoperative period
Neo-adjuvant
chemotherapy
Post-operative
chemotherapy
n patients
(%)
n cycles
(%)
n patients
(%)
n cycles
(%)
Total 30 (100) 93 (100) 24 (100) 72 (100)
Dose delay 12 (40) 14 (15) 8 (33) 8 (11)
Dose reduction 2 (7) 5 (5) 5 (21) 13 (18)
Switch to other types
of chemotherapy
0 0 2 (8) 4 (6)
n¼number.
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Figure 1 Kaplan–Meier curves for PFS and OS.
Table 1 Patient characteristics
n (%)
Total of patients 30
Age (years)
Median (range) 65 (44–81)
Menopausal status
Pre 1 (3)
Peri 1 (3)
Post 28 (93)
Histological subtype
Serous 27 (90)
Clear cell 1 (3)
Endometrioid
Grade 1 1 (3)
Grade 2 1 (3)
Type of NACT
Paclitaxel/carboplatin 25 (83)
Doxorubicin/cisplatin 3 (10)
Epirubicin/carboplatin 1 (3)
Carboplatin 1 (3)
Number of cycles before IDS
3 27 (90)
4 3 (10)
n¼number of patients; NACT¼neoadjuvant chemotherapy; IDS¼ interval
debulking surgery.
Neoadjuvant chemotherapy followed by interval debulking surgery
I Vandenput et al
246
British Journal of Cancer (2009) 101(2), 244–249 & 2009 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sThe response to chemotherapy as determined by a histopatho-
logical assessment of the tumour is identified as a new prognostic
marker in endometrial cancer. In patients with ovarian cancer
undergoing IDS, Le et al (2006, 2007) assessed four features of
tumour necrosis (necrosis, fibrosis, macrophage infiltration and
Figure 2 (A and B) Representative slides of good and poor histopathological response on chemotherapy in the omentum. (A) Good chemotherapy
response (H&E  40) is based on tumour inflammation (large white arrow), fibrosis (small white arrow), foamy macrophages (large black arrow) and
tumour infiltration (small black arrow). (B) Poor chemotherapy response (H&E  40) is based on the absence of regression criteria and multifocal tumour
infiltration (black arrow). (C–E) Histopathological features of tumour regression (indicated by arrow) in endometrial cancer. C (H&E  40): psammoma
bodies; D (H&E  40): foamy macrophages; E (H&E  40): necrosis.
Table 3 Results of scoring all histopathological features (n¼8) of
tumour regression in uterus and omentum
Histopathological features Uterus n (%) Omentum n (%)
Necrosis
0/1+ 22 (92) 19 (79)
2+ 1 (4) 3 (13)
3+ 1 (4) 2 (8)
Fibrosis
0/1+ 15 (63) 6 (25)
2+ 7 (29) 6 (25)
3+ 2 (8) 12 (50)
Inflammation
0/1+ 20 (83) 20 (83)
2+ 2 (8) 1 (4)
3+ 2 (8) 3 (13)
Psammoma bodies
0/1+ 20 (83) 15 (63)
2+ 4 (17) 5 (21)
3+ 0 4 (17)
Foamy macrophages
0/1+ 22 (92) 21 (88)
2+ 1 (4) 0
3+ 1 (4) 3 (13)
Foreign-body giant cells
0/1+ 24 (100) 22 (92)
2+ 0 2 (8)
3+ 0 0
Giant tumour cells
0/1+ 21 (88) 20 (83)
2+ 3 (13) 3 (13)
3+ 0 1 (4)
Tumour infiltration
1+ 12 (50) 12 (50)
2+ 3 (13) 3 (13)
3+ 9 (38) 9 (38)
n¼number of patients.
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Figure 3 Correlation of all histopathological features with recurrence
and overall survival.
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stumour-induced inflammation). They concluded that a higher
composite pathological tumour response score was significantly
correlated with a prolonged progression-free survival (P¼0.0016)
and OS (P¼0.017). In contrast, Sassen et al (2007) could not
confirm this correlation between histopathological features and
OS. Residual tumour size was the only criterion significantly
correlated with treatment response and OS. In the absence of any
data on this in endometrial cancer, we used the same criteria as
that used for ovarian cancer (Sassen et al, 2007). In this study, a
histopathological score indicative of chemosensitivity was sig-
nificantly correlated with recurrence and OS. Especially, tumour
infiltration and necrosis were related to better PFS and OS.
In current practice, patients with stage IV endometrial cancer
receive either no surgery (systemic treatment only) or primary
debulking surgery. An overview of studies exploring the latter is
presented in Table 4. From this table, it seems that PFS and OS
depend on the amount of residual disease and that patients
without residual tumour have a better outcome. In addition,
28–48% of patients were unable to have optimal cytoreduction
and 18–38% were considered inoperable. In contrast, this study
revealed 24 patients (80%) who underwent optimal cytoreduction
(R p1cm), of whom 22 (92%) were with no residual tumour. Only
4 (14%) patients were considered inoperable. The median PFS of
13 months corresponds to that of previous reports (Memarzadeh
et al, 2002; Thomas et al, 2007).
In addition, the data on postoperative complications were better
in this analysis. In studies depicted in Table 4, minor postoperative
complications (wound infection, prolonged time to bowel move-
ment, urinary tract infection, pneumonia and deep venous
thrombosis) after primary debulking occurred in 36–39% of the
cases. Major life-threatening complications (small bowel obstruc-
tion, myocardial infarction and pulmonary embolism) occurred in
13% of cases (Bristow et al, 2001; Memarzadeh et al, 2002). These
data contrast to the current analysis in which minor and major
postoperative complications were observed in 13 and 4% of cases,
respectively.
Thus, comparing the data on efficacy and morbidity from
studies depicted in Table 4, with the current findings, it seems that
the investigated strategy results in a higher chance for complete
surgical resection with less postoperative morbidity.
The value of IDS has been a focus of interest for a long time in the
advanced stage of ovarian cancer. Numerous retrospective studies
have documented the potential benefit of IDS in ovarian cancer.
Recently, the results of a randomised trial of EORTC-GCG/NCIC-
CTG comparing primary debulking with IDS after NACT in stage
IIIc–IV ovarian, fallopian tube and peritoneal cancer were presented
by I Vergote et al (Vergote et al, 2008). The data showed a similar OS
and PFS. Vergote et al (Vergote et al, 2008) concluded that, in very
advanced stage IIIc and IV ovarian carcinoma, as included in their
study, NACT could be considered as an alternative for primary
debulking surgery because of the lower morbidity of IDS compared
with primary debulking. A majority of our patients had serous-type
endometrial cancer stage IV based on transperitoneal spread,
resembling the EORTC-GCG/NCIC-CTG study population. Given
these similarities and given our current findings, we believe that the
data obtained in stage IIIc ovarian cancer might be extrapolated to
endometrial cancer with transperitoneal spread (stage IV). This is an
important notion as a large comparative study in endometrial cancer
with transperitoneal spread is unlikely to be feasible.
In conclusion, the degree of tumour regression after NACT for
advanced stage endometrial cancer was identified as a new
prognostic marker. The use of NACT for stage IV endometrial
cancer resulted in an 80% optimal cytoreduction in patients,
wherein an attempt for complete resection was made with a low
postoperative morbidity rate. In combination with the most recent
data in ovarian cancer with transperitoneal spread, the current
data suggest that NACT followed by IDS is a valuable option for
endometrial cancer with transperitoneal spread.
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